Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 15,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $75.15, for a total transaction of $1,127,250.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
G Bradley Cole also recently made the following trade(s):
- On Tuesday, February 12th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The stock was sold at an average price of $80.87, for a total transaction of $1,213,050.00.
- On Tuesday, January 8th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The stock was sold at an average price of $67.03, for a total transaction of $1,005,450.00.
GHDX traded down $1.99 on Friday, hitting $74.52. The company had a trading volume of 19,189 shares, compared to its average volume of 377,153. Genomic Health, Inc. has a 52-week low of $30.04 and a 52-week high of $92.18. The firm has a market capitalization of $2.80 billion, a PE ratio of 70.95 and a beta of 0.97.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Royce & Associates LP grew its position in Genomic Health by 22.8% in the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after purchasing an additional 273 shares during the period. Advisor Group Inc. grew its position in Genomic Health by 34.9% in the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after purchasing an additional 516 shares during the period. Pacer Advisors Inc. bought a new stake in Genomic Health in the 3rd quarter worth approximately $171,000. Quantamental Technologies LLC bought a new stake in Genomic Health in the 4th quarter worth approximately $180,000. Finally, Trexquant Investment LP bought a new stake in Genomic Health in the 3rd quarter worth approximately $202,000. 91.69% of the stock is owned by institutional investors.
A number of analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “strong-buy” rating and set a $97.00 target price (up from $86.00) on shares of Genomic Health in a report on Thursday, February 21st. ValuEngine upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 13th. Piper Jaffray Companies raised their price objective on shares of Genomic Health to $86.00 and gave the stock a “neutral” rating in a report on Thursday, February 21st. BidaskClub lowered shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Finally, Oppenheimer began coverage on shares of Genomic Health in a report on Wednesday, December 19th. They issued a “market perform” rating for the company. Nine investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $63.13.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
See Also: Ex-Dividend
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.